Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma

Drug Delivery
Junfeng YeXiaohong Du

Abstract

Combinational therapy is usually considered as a preferable approach for effective cancer therapy. Especially, combinational chemotherapies targeting different molecular targets are of particular interest due to its high flexibility as well as efficiency. In our study, the surface of silica nanoparticles (SLN) was modified with low-density lipoprotein (LDL) to construct platform (LDL-SLN) capable of specifically targeting low-density lipoprotein receptors (LDLRs) that overexpressing in hepatocellular carcinoma (HCC). In addition, the versatile drug loading capacity of LDL-SLN was employed to fabricate a preferable drug delivery system to co-deliver sorafenib (Sor) and doxorubicin (Dox) for combinational chemotherapy of HCC. Our results revealed that the LDL-SLN/Sor/Dox nanoparticles with size around 100 nm showed preferable stability in physiological environments. Moreover, the LDL-SLN/Sor/Dox could target LDLR overexpressed HepG2 cells. More importantly, both in vitro and in vivo experiments demonstrated that the LDL-SLN/Sor/Dox exerted elevated antitumor efficacy compared to Sor or Dox alone, which indicated that LDL-SLN/Sor/Dox could be a powerful tool for effective combinational chemotherapy of HCC.

References

Apr 24, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jolien TolIris D Nagtegaal
Jan 28, 2015·Journal of Biomaterials Science. Polymer Edition·Hongbo WuXudong Wei
Feb 5, 2016·Colloids and Surfaces. B, Biointerfaces·Yanan XiaoNa Zhang
Aug 9, 2016·International Journal of Oncology·Hanxiao XuKongming Wu
Sep 24, 2016·International Journal of Nanomedicine·Diogo Silva PellosiFabiana Quaglia
Jan 26, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jieke YanHongwei Wang
May 10, 2017·Materials Science & Engineering. C, Materials for Biological Applications·Jia-Kang WangXiao-Jia Chen
Mar 8, 2018·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Man AoYazhou Ao
Mar 23, 2018·International Journal of Nanomedicine·Conglian YangZhiping Zhang
Aug 28, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Ling-Xin MengHui-Yun Wang
Sep 14, 2015·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Carmen StoffelenJurriaan Huskens
Feb 7, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Chao LinJie Ren
Apr 28, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·J RuffU Simon
Dec 28, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Junpeng ShiHongwu Zhang

❮ Previous
Next ❯

Citations

Oct 4, 2020·IET Nanobiotechnology·Hasnat Tariq, Syed Ali Imran Bokhari
Oct 23, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Haroon IqbalHuabing Chen
May 26, 2021·Biomaterials Science·Mohammed Mehadi Hassan ChowdhuryMd Nurunnabi
Jul 17, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Mohamed Fawzi KabilIbrahim M El-Sherbiny

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
xenograft
flow cytometry
fluorescence imaging

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.